for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Portola Pharmaceuticals Inc

PTLA.OQ

Latest Trade

30.37USD

Change

0.15(+0.50%)

Volume

1,357,733

Today's Range

29.88

 - 

30.72

52 Week Range

14.81

 - 

37.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
30.22
Open
30.18
Volume
1,357,733
3M AVG Volume
22.88
Today's High
30.72
Today's Low
29.88
52 Week High
37.90
52 Week Low
14.81
Shares Out (MIL)
77.48
Market Cap (MIL)
2,341.34
Forward P/E
-9.50
Dividend (Yield %)
--

Next Event

Q3 2019 Portola Pharmaceuticals Inc Earnings Release

Latest Developments

More

Portola Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Portola Pharmaceuticals Announces Proposed Offering Of Common Stock

Portola Pharmaceuticals Q2 GAAP Loss Per Share $0.97

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Portola Pharmaceuticals Inc

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Industry

Biotechnology & Drugs

Contact Info

270 E Grand Ave Ste 22

+1.650.2446864

https://www.portola.com/

Executive Leadership

Hollings C. Renton

Independent Chairman of the Board

Scott Garland

President, Chief Executive Officer

Mardi C. Dier

Chief Financial Officer, Executive Vice President, Business Officer

Ernie Meyer

Chief Human Resource Officer, Executive Vice President

John B. Moriarty

Executive Vice President, General Counsel, Secretary

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-4.760

2017

-4.810

2018

-5.010

2019(E)

-3.180
Price To Earnings (TTM)
--
Price To Sales (TTM)
29.24
Price To Book (MRQ)
3,471.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
46,923.57
LT Debt To Equity (MRQ)
43,629.46
Return on Investment (TTM)
-85.08
Return on Equity (TTM)
-69.76

Latest News

BRIEF-Portola Pharmaceuticals Receives $100 Mln Milestone Payment From Healthcare Royalty Partners For FDA Approval Of Andexxa

* PORTOLA PHARMACEUTICALS RECEIVES $100 MILLION MILESTONE PAYMENT FROM HEALTHCARE ROYALTY PARTNERS FOR FDA APPROVAL OF ANDEXXA® Source text for Eikon: Further company coverage:

BRIEF-Portola Pharmaceuticals Q1 Loss Per Share $1.28

* PORTOLA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-U.S. FDA Approves Portola Pharmaceuticals’ Andexxa

* U.S. FDA APPROVES PORTOLA PHARMACEUTICALS’ ANDEXXA®, FIRST AND ONLY ANTIDOTE FOR THE REVERSAL OF FACTOR XA INHIBITORS

BRIEF-Portola Pharmaceuticals Plans To Appeal Negative CHMP Opinion For Betrixaban In The European Union

* PORTOLA PHARMACEUTICALS RECEIVES AND PLANS TO APPEAL NEGATIVE CHMP OPINION REGARDING MARKETING AUTHORIZATION FOR BETRIXABAN IN THE EUROPEAN UNION

EMA panel recommends against Portola's clot prevention drug

A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc's oral blood thinner, saying the benefits of the drug did not outweigh risks.

BRIEF-EMA Panel Recommends Against Approval Of Portola Drug For Preventing Blood Clots Betrixiban

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL OF PORTOLA PHARMACEUTICALS' DRUG FOR PREVENTING BLOOD CLOTS BETRIXIBAN Source text (http://bit.ly/2pBz519) Further company coverage:

BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study

* PORTOLA PHARMACEUTICALS ANNOUNCES NEW INTERIM RESULTS FROM ONGOING ANNEXA-4 STUDY OF FACTOR XA INHIBITOR REVERSAL AGENT ANDEXXA® (ANDEXANET ALFA) IN PATIENTS WITH LIFE-THREATENING BLEEDING

BRIEF-Portola Pharmaceuticals Q4 Loss Per Share $1.41

* PORTOLA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION (BLA) FOR ANDEXXA® (ANDEXANET ALFA)

BRIEF-U.S. FDA Approves Prior Approval Supplement For Launch Of Portola Pharmaceuticals' Betrixaban

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES PRIOR APPROVAL SUPPLEMENT FOR COMMERCIAL LAUNCH OF PORTOLA PHARMACEUTICALS’ NOVEL ORAL ANTICOAGULANT BEVYXXA® (BETRIXABAN)

BRIEF-Portola Provides Update On European Marketing Authorization Application For Betrixaban

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR BETRIXABAN

BRIEF-Portola Pharmaceuticals provides update on Bevyxxa commercial launch

* Portola Pharmaceuticals provides update on Bevyxxa(betrixaban) commercial launch

BRIEF-Portola Pharmaceuticals appoints John Lawrence as chief medical officer

* Portola Pharmaceuticals appoints industry veteran John H. Lawrence, M.D., as senior vice president of product development and chief medical officer Source text for Eikon: Further company coverage:

BRIEF-Portola announces pricing of public offering of common stock at $55 per share

* Portola announces pricing of public offering of common stock

BRIEF-Portola Pharma announces proposed offering of common stock

* Portola Pharmaceuticals announces proposed offering of common stock

BRIEF-Portola Pharmaceuticals ‍says due date for review of BLA for Andexxa is Feb 2, 2018

* Portola Pharmaceuticals announces Andexxa (Andexanet Alfa) Biologics License Application resubmission accepted for review by U.S. FDA

BRIEF-Portola Pharmaceuticals reports Q2 loss per share of $1.22

* Portola Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Portola announces resubmission of BLA for Andexxa

* Portola Pharmaceuticals announces resubmission of biologics license application for Andexxa (andexanet alfa)

Portola shares soar after FDA approves clot preventing drug

The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

U.S. FDA approves Portola blood-thinner to prevent blood clots

The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc. to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up